GH and IGF-I levels and tumor shrinkage in response to first generation somatostatin receptor ligands in acromegaly: a comparative study between two reference centers for pituitary diseases in Brazil

Manosso, Karina Zanlorenzi Basso; Sampaio, Carolina Labigalini; Kasuki, Leandro; Antunes, Ximene; Boguszewski, César Luiz

doi:10.1007/s12020-021-02766-2

Cited by 4 publications

(1 citation statement)

References 38 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…По данным исследований, в неселективной выборке пациентов с акромегалией частота достижения биохимического контроля на фоне применения октреотида составила 25-45% [6,12,13]. Этим показателям соответствуют данные Российского регистра гипоталамо-гипофизарных заболеваний, согласно которым в целом частота биохимического контроля на фоне медикаментозного лечения акромегалии составила 32% [14].…”

Section: эффективность медикаментозной терапии октреотидом продленног...unclassified

Octreotide in the treatment of acromegaly – the possibilities of high-dose therapy

Ilovayskaya

2022

Medicinskij sovet

View full text Add to dashboard Cite

Octreotide is a first-generation somatostatin analog that has been used for 40 years for the medical treatment of acromegaly, both after neurosurgical intervention and as first-line treatment. The frequency of biochemical control against the background of extended-acting octreotide varies from 25 to 56% depending on growth hormone and IGF-1 levels at the disease debut, presence of previous surgery, patient gender and age, treatment compliance and the dose of octreotide used. Longterm clinical experience with prolonged-acting octreotide demonstrates that more than half of patients require an increase in dosage to 30 mg or higher. If during treatment with Octreotide in a dose of 30 mg for 3 months there is no normalization of IGF-1 level, but there was a decrease of 50% or more of the initial level, further dose increase to 40 mg is possible, because this increases the effectiveness of treatment without increasing the frequency of side effects. Foreign researchers have shown that high doses of Octreotide (60 mg every 28 days) can improve biochemical control in patients who have not fully responded to therapy with doses of 30–40 mg of extended-acting Octreotide. Further studies are needed to determine the optimal dose of prolonged octreotide in acromegaly therapy, both at the start of treatment and during treatment. Management of patients by a team of specialists involved in the treatment of pituitary tumors will allow faster achievement of biochemical control of acromegaly.

show abstract

Section: эффективность медикаментозной терапии октреотидом продленног...unclassified